Syntekabio announced its participation at the upcoming Bio-IT World Conference & Expo. The company has recently launched its drug discovery services in the US and Europe and is introducing STB LaunchPad, Syntekabio's proprietary disease-agnostic technology platform that is able to generate hits, leads, and drug candidates against multiple targets. Viable leads are further optimized and experimentally validated in cooperation with its global network of contract research organizations (CROs), and an IND-enabling package then is delivered to the client.

AI technologies can supercharge data analysis and facilitate rapid drug discovery, but they still require significant case-by-case tailoring and experimental validation. Dr. Kruzel will present Syntekabio's disease-agnostic approach to AI-driven drug discovery that yields viable drug candidates. Bringing together biology, AI, and cloud technologies, Syntekabio is working in a factory-like mode, continuously generating novel and viable drug candidates for a wide range of diseases.

The goal: don't make the patients wait.